We have located links that may give you full text access.
Radiosynthesis and Preclinical Evaluation of an α 2A -Adrenoceptor Tracer Candidate, 6-[ 18 F]Fluoro-marsanidine.
Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging 2019 Februrary 2
PURPOSE: The α2 -adrenoceptors mediate many effects of norepinephrine and epinephrine, and participate in the regulation of neuronal, endocrine, cardiovascular, vegetative, and metabolic functions. Of the three receptor subtypes, only α2A and α2C are found in the brain in significant amounts. Subtype-selective positron emission tomography (PET) imaging of α2 -adrenoceptors has been limited to the α2C subtype. Here, we report the synthesis of 6-[18 F]fluoro-marsanidine, a subtype-selective PET tracer candidate for α2A -adrenoceptors, and its preclinical evaluation in rats and mice.
PROCEDURES: 6-[18 F]Fluoro-marsanidine was synthesized using electrophilic F-18 fluorination with [18 F]Selectfluor bis(triflate). The tracer was evaluated in Sprague Dawley rats and in α2A -knockout (KO) and wild-type (WT) mice for subtype selectivity. In vivo PET imaging and ex vivo brain autoradiography were performed to determine the tracer distribution in the brain. The specificity of the tracer for the target was determined by pretreatment with the subtype-non-selective α2 -agonist medetomidine. The peripheral biodistribution and extent of metabolism of 6-[18 F]fluoro-marsanidine were also analyzed.
RESULTS: 6-[18 F]Fluoro-marsanidine was synthesized with [18 F]Selectfluor bis(triflate) in a radiochemical yield of 6.4 ± 1.7 %. The molar activity was 3.1 to 26.6 GBq/μmol, and the radiochemical purity was > 99 %. In vivo studies in mice revealed lower uptake in the brains of α2A -KO mice compared to WT mice. The results for selectivity were confirmed by ex vivo brain autoradiography. Blocking studies revealed reduced uptake in α2A -adrenoceptor-rich brain regions in pretreated animals, demonstrating the specificity of the tracer. Metabolite analyses revealed very rapid metabolism of 6-[18 F]fluoro-marsanidine with blood-brain barrier-permeable metabolites in both rats and mice.
CONCLUSION: 6-[18 F]Fluoro-marsanidine was synthesized and evaluated as a PET tracer candidate for brain α2A -adrenoceptors. However, rapid metabolism, extensive presence of labeled metabolites in the brain, and high non-specific uptake in mouse and rat brain make 6-[18 F]fluoro-marsanidine unsuitable for α2A -adrenoceptor targeting in rodents in vivo.
PROCEDURES: 6-[18 F]Fluoro-marsanidine was synthesized using electrophilic F-18 fluorination with [18 F]Selectfluor bis(triflate). The tracer was evaluated in Sprague Dawley rats and in α2A -knockout (KO) and wild-type (WT) mice for subtype selectivity. In vivo PET imaging and ex vivo brain autoradiography were performed to determine the tracer distribution in the brain. The specificity of the tracer for the target was determined by pretreatment with the subtype-non-selective α2 -agonist medetomidine. The peripheral biodistribution and extent of metabolism of 6-[18 F]fluoro-marsanidine were also analyzed.
RESULTS: 6-[18 F]Fluoro-marsanidine was synthesized with [18 F]Selectfluor bis(triflate) in a radiochemical yield of 6.4 ± 1.7 %. The molar activity was 3.1 to 26.6 GBq/μmol, and the radiochemical purity was > 99 %. In vivo studies in mice revealed lower uptake in the brains of α2A -KO mice compared to WT mice. The results for selectivity were confirmed by ex vivo brain autoradiography. Blocking studies revealed reduced uptake in α2A -adrenoceptor-rich brain regions in pretreated animals, demonstrating the specificity of the tracer. Metabolite analyses revealed very rapid metabolism of 6-[18 F]fluoro-marsanidine with blood-brain barrier-permeable metabolites in both rats and mice.
CONCLUSION: 6-[18 F]Fluoro-marsanidine was synthesized and evaluated as a PET tracer candidate for brain α2A -adrenoceptors. However, rapid metabolism, extensive presence of labeled metabolites in the brain, and high non-specific uptake in mouse and rat brain make 6-[18 F]fluoro-marsanidine unsuitable for α2A -adrenoceptor targeting in rodents in vivo.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app